Question 1HIV (human immunodeficiency virus) epidemic in UgandaUganda, an East African country south of the Sahara, is grappling with the HIV pandemic HIV as early as the 1990s, when 18.5% of Ugandans were infected at its peak (Foundation, 2012). Currently, out of a population of 33.6 million people, 1.5 million live with AIDS, with a prevalence rate of 7.2% among 15-49 year olds. Among those infected, 190,000 are children (UNAIDS, 2012). In the mid-1990s and until recently, HIV prevalence began to gradually decline to 6.4% due to government ABC policies of abstaining, being faithful, using a condom. However, reports show a steady increase in HIV prevalence. , which currently stands at 7.3% (8.3% among women), (commission, 2014), mainly due to HIV prevention programs focusing only on abstinence, the increase risky sexual behavior, particularly among married couples, and the availability of ARVs which have reduced people's fear of HIV. scourge. The number of new infections has been estimated at 150,000 per year, including 20,600 children (AVERT, 2012). HIV/AIDS has had devastating effects on the Ugandan population, including: a growing number of orphans (1,000,000 children aged 0-17 years according to UNAIDS 2012 estimates, representing approximately 20% of the infant population). According to a UNICEF report, grandmothers look after approximately 45% of orphans in certain regions most affected by the scourge of AIDS (UNICEF, 2007); Increased poverty levels due to long duration of illness, inability to work, cost of medicine and hospital bills, loss of productive time to care for the sick, as well as funeral costs; business profitability has been hampered by absenteeism...... middle of paper ...... with the big numbers and there should be facilities to do the basic examinations needed to start HAART, for example a complete blood count, kidney and liver function tests, as well as machines to perform a CD4 count since this is the basis for starting HAART. • Those who become eligible should receive comprehensive adherence counseling to understand the implications of starting lifelong ARVs at a higher CD4 threshold. After successful implementation of the program, there should be continued monitoring to establish the use of ARVs at this CD4 threshold and the challenges faced by patients, health workers and all different stakeholders should be identified early and addressed in a timely manner to ensure successful implementation and determine areas for future research.Question 7Research to improve decision making regarding this policy